Stocknews
FTSE Bursa Malaysia KLCI (^KLSE) 1,646.53 14.83 (0.90%)
updated at: Wed, 09 Dec 2020, 05:25PM MYT

UOB Kay Hian Research raises Duopharma target price

DPHARMA
DPHARMA
Original Source From TheStar Publish at Tue, 19 May 2020, 11:17AM

“We continue to like Duopharma for its: a) leading position as a local producer but with ample areas of growth, particularly in the prescription market; b) efforts to realise regional ambitions with strategic tie-ups that grant exclusive rights to sell niche drugs to the Asean region; and c) robust earnings growth. Duopharma offers decent 13.4% three-year earnings CAGR in 2019-22, ” it said.

Top Participation View More
updated at: Fri, 29 May 2020 MYT
Participation (%)
Bought (MYR)
Sold (MYR)
Net
Foreign
( 24,36 % )
2.31 B 2.23 B 77.37 M
Local Institution
( 39,38 % )
3.66 B 3.67 B 0.00 B
Local Retail
( 36,26 % )
3.34 B 3.41 B -0.07 B